CY1113684T1 - Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη - Google Patents

Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη

Info

Publication number
CY1113684T1
CY1113684T1 CY20101101093T CY101101093T CY1113684T1 CY 1113684 T1 CY1113684 T1 CY 1113684T1 CY 20101101093 T CY20101101093 T CY 20101101093T CY 101101093 T CY101101093 T CY 101101093T CY 1113684 T1 CY1113684 T1 CY 1113684T1
Authority
CY
Cyprus
Prior art keywords
microbiaka
kai
arginine
lysine
mobile
Prior art date
Application number
CY20101101093T
Other languages
English (en)
Inventor
Deborah O'neil
Original Assignee
Novabiotics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0418414.9A external-priority patent/GB0418414D0/en
Application filed by Novabiotics Limited filed Critical Novabiotics Limited
Publication of CY1113684T1 publication Critical patent/CY1113684T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ένα πεπτίδιο που περιλαμβάνει αμινοξέα σύμφωνα με τον τύπο (I):((X)1(Y)m)n όπου τα 1, m και n είναι ακέραιοι από το 0 μέχρι το 10, το Χ και Υ, που μπορεί να είναι ίδια ή διαφορετικά, είναι ένα αμινοξύ που επιλέγεται από την ομάδα που αποτελείται από υδρόφοβα αμινοξέα και/ ή κατιοντικά αμινοξέα, για χρήση σαν φάρμακο.
CY20101101093T 2004-08-18 2010-11-30 Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη CY1113684T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0418414.9A GB0418414D0 (en) 2004-08-18 2004-08-18 Peptide
US7979505A 2005-03-14 2005-03-14
EP05778505A EP1778720B1 (en) 2004-08-18 2005-08-18 Antimicrobial peptides comprising an arginine- and/or lysine-containing motif

Publications (1)

Publication Number Publication Date
CY1113684T1 true CY1113684T1 (el) 2016-06-22

Family

ID=35907779

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101093T CY1113684T1 (el) 2004-08-18 2010-11-30 Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη

Country Status (25)

Country Link
US (4) US7847059B2 (el)
EP (5) EP1778720B1 (el)
JP (1) JP5020078B2 (el)
KR (1) KR101234780B1 (el)
CN (3) CN101031583B (el)
AT (1) ATE479704T1 (el)
AU (1) AU2005273638B2 (el)
BR (1) BRPI0514420B1 (el)
CA (2) CA2575058C (el)
CY (1) CY1113684T1 (el)
DE (1) DE602005023315D1 (el)
DK (2) DK1778720T3 (el)
ES (1) ES2613027T3 (el)
GB (1) GB2431404A (el)
HK (1) HK1105982A1 (el)
IL (2) IL180727A (el)
MX (1) MX2007002057A (el)
NO (1) NO342832B1 (el)
NZ (2) NZ584340A (el)
PL (1) PL1778720T3 (el)
PT (2) PT1778720E (el)
RU (1) RU2396273C2 (el)
SG (3) SG155211A1 (el)
SI (1) SI1778720T1 (el)
WO (1) WO2006018652A2 (el)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838331A4 (en) 2004-12-15 2012-12-26 Univ Colorado ANTIMICROBIAL PEPTIDES AND METHODS OF USE THEREOF
AU2006327973B2 (en) * 2005-12-22 2012-04-12 Novabiotics Limited Cyclic antimicrobial peptides
US9181303B2 (en) 2005-12-22 2015-11-10 Novabiotics Limited Treatment of bacterial infections with cyclic antimicrobial peptides
AU2012203804B2 (en) * 2005-12-22 2014-10-16 Novabiotics Limited Cyclic antimicrobial peptides
GB0702021D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0702022D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0702020D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
EP2178549B1 (en) * 2007-07-26 2016-09-14 Revance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
US20100150985A1 (en) * 2008-04-24 2010-06-17 George Just Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making the Same
GB0817121D0 (en) * 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
CA2739842A1 (en) * 2008-10-06 2010-04-15 The Regents Of The University Of Colorado, A Body Corporate Antimicrobial peptides and methods of use
DK2356135T3 (en) * 2008-11-05 2017-12-04 Wyeth Llc IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE
US20100184684A1 (en) 2009-01-06 2010-07-22 C3 Jian, Inc. Antibacterial and antifungal peptides
FR2941231B1 (fr) 2009-01-16 2016-04-01 Sederma Sa Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
WO2010141760A2 (en) * 2009-06-05 2010-12-09 The Regents Of The University Of Colorado, A Body Corporate Antimicrobial peptides
JP5664992B2 (ja) * 2009-08-26 2015-02-04 国立大学法人名古屋大学 細胞特異的ペプチド及びその用途
WO2011113604A1 (en) * 2010-03-17 2011-09-22 Universität Regensburg Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein
CN102206250B (zh) 2010-03-29 2017-03-15 翔升科技股份有限公司 低血球溶解性的抗微生物肽、药物组合物及其用途
GB201016733D0 (en) 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
RU2449805C1 (ru) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
ES2679995T3 (es) 2011-03-11 2018-09-03 Vib Vzw Moléculas y métodos para la inhibición y detección de proteínas
DE102011077071A1 (de) * 2011-06-07 2012-12-13 Beiersdorf Ag Wirkstoffkombinationen aus Epsilon-Polylysin und Climbazol
KR101345333B1 (ko) * 2011-12-30 2013-12-30 조선대학교산학협력단 라이신 및 트립토판 잔기가 ４번 반복된 신규한 항균 및 항진균 펩타이드 및 이의 용도
GB201204457D0 (en) * 2012-03-14 2012-04-25 Novabiotics Ltd Polypeptides and their use
WO2013142184A1 (en) 2012-03-19 2013-09-26 Yale University Antimicrobial compositions and methods
KR102141254B1 (ko) 2012-03-23 2020-08-04 아미크로베, 인코포레이티드. 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
US9662372B2 (en) 2013-02-20 2017-05-30 Biolog, Inc. Compositions and methods to inactivate and/or reduce production of microbial toxins
RU2683651C2 (ru) * 2013-06-18 2019-04-01 Иван Дмитриевич Захаров Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе
GB201409451D0 (en) 2014-05-28 2014-07-09 Ipabc Ltd Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms
US20170119814A1 (en) * 2014-06-17 2017-05-04 Albert Einstein College Of Medicine, Inc. Therapeutic nanoparticles and methods thereof
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
CN104311627B (zh) * 2014-10-29 2018-04-10 中山大学 一种抗菌肽的合成方法和应用
PL3106172T3 (pl) * 2015-06-15 2020-12-28 B. Braun Melsungen Ag Środek aktywny przeciwdrobnoustrojowo i jego zastosowanie
US20210213096A1 (en) * 2016-02-19 2021-07-15 Forschungszentrum Borstel Leibniz-Zentrum Fur Medizin Und Biowssenschaften Means and methods for treating bacterial infections
WO2018144545A1 (en) 2017-01-31 2018-08-09 Stc.Unm Arginine-rich polypeptide compositions and methods of using same
US11285189B2 (en) 2017-04-06 2022-03-29 Amicrobe, Inc. Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
US11931333B1 (en) * 2019-05-28 2024-03-19 Peter Van Horn Topical treatment of herpes infections
CN112457375B (zh) * 2019-09-06 2022-12-02 韩苏 多肽化合物及其制备方法与应用
CN113264987B (zh) * 2021-05-31 2023-11-17 安徽农业大学 具有抗真菌和清除自由基活性的环色-苏-缬-异亮-亮肽及制备方法
CN113307848B (zh) * 2021-05-31 2023-11-17 安徽农业大学 具有抗真菌和清除自由基活性的环色-丝-缬-异亮-亮肽及制备方法
CN115669843A (zh) * 2022-10-26 2023-02-03 中国农业大学 一种采用高压微射流结合混合肽有效杀灭芽孢的方法
CN116332777A (zh) * 2023-02-20 2023-06-27 华中科技大学 二芳基苯甲胺类化合物、制备及作为载体合成多肽的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
EP0050271A1 (de) 1980-10-14 1982-04-28 Maschinenfabrik Rieter Ag Automatische Auswechselvorrichtung von auslaufenden Vorgarnspulen für eine Spinnmaschine
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
EP0400372B1 (de) * 1989-05-30 1995-08-02 Siemens Aktiengesellschaft CMOS-ECL-Wandler
CA2061862A1 (en) * 1991-03-04 1992-09-05 Jonathan Duvick Natural and synthetic proteins with inhibitory activity towards pathogenic microorganisms
JP3022615B2 (ja) * 1991-03-13 2000-03-21 日清製粉株式会社 ε−ポリリジンの製造方法
JP3000490B2 (ja) * 1991-04-08 2000-01-17 チッソ株式会社 抗白癬菌剤
US5486503A (en) * 1991-11-01 1996-01-23 The Trustees Of Boston University Anti-fungal histatin-based peptides
EP0752885B1 (en) 1992-09-25 2003-07-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JP3655359B2 (ja) * 1995-06-29 2005-06-02 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの洗浄および消毒用組成物
US5714577A (en) * 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
JPH11113779A (ja) * 1997-10-14 1999-04-27 Asahi Chem Ind Co Ltd 除菌ウェットティッシュ
EA200101086A1 (ru) * 1999-04-15 2002-04-25 Эли Лилли Энд Компани Антигрибковые агенты, выделенные из pseudomonas syringae
US20020001582A1 (en) * 1999-04-21 2002-01-03 Charter Edward A. Methods and compositions for inhibiting microbial growth
JP2001264707A (ja) * 2000-03-22 2001-09-26 Chisso Corp コンタクトレンズ用消毒保存用溶液
JP2002020320A (ja) * 2000-06-30 2002-01-23 Santen Pharmaceut Co Ltd 点眼液用防腐剤
FR2811666B1 (fr) * 2000-07-13 2005-04-01 Entomed S A Peptides antifongiques et/ou antibacteriens, leurs preparations et les compositions les contenant
CN1336383A (zh) * 2000-07-29 2002-02-20 中国科学院昆明动物研究所 大蹼铃蟾抗菌肽及其制备方法和在制药中的应用
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
EP1502949B1 (en) * 2002-04-25 2010-11-24 Toagosei Co., Ltd. Antimicrobial polypeptide and utilization thereof
JP4461727B2 (ja) * 2003-07-18 2010-05-12 チッソ株式会社 外用剤組成物
US20080193616A1 (en) * 2007-02-13 2008-08-14 The Coca-Cola Company Beverage compositions comprising polylysine and at least one weak acid

Also Published As

Publication number Publication date
SG188092A1 (en) 2013-03-28
US20120071398A1 (en) 2012-03-22
SG10201606278UA (en) 2016-09-29
EP3147293B1 (en) 2022-05-04
NZ553494A (en) 2010-07-30
JP2008509980A (ja) 2008-04-03
CA2575058C (en) 2017-09-12
PL1778720T3 (pl) 2011-03-31
CN103360485A (zh) 2013-10-23
DE602005023315D1 (de) 2010-10-14
HK1105982A1 (en) 2008-02-29
NO342832B1 (no) 2018-08-13
EP1778720B1 (en) 2010-09-01
JP5020078B2 (ja) 2012-09-05
KR101234780B1 (ko) 2013-02-20
US8350003B2 (en) 2013-01-08
BRPI0514420B1 (pt) 2022-05-17
PT1927597T (pt) 2017-02-10
US8088888B2 (en) 2012-01-03
DK1778720T3 (da) 2010-11-29
US20070244044A1 (en) 2007-10-18
IL213319A0 (en) 2011-07-31
AU2005273638A1 (en) 2006-02-23
PT1778720E (pt) 2010-11-29
ATE479704T1 (de) 2010-09-15
IL180727A0 (en) 2007-06-03
WO2006018652A3 (en) 2006-07-13
AU2005273638B2 (en) 2011-09-29
CA2575058A1 (en) 2006-02-23
GB2431404A (en) 2007-04-25
US20110021415A1 (en) 2011-01-27
CN101031583A (zh) 2007-09-05
EP3141559A1 (en) 2017-03-15
US7847059B2 (en) 2010-12-07
RU2396273C2 (ru) 2010-08-10
EP1927597A1 (en) 2008-06-04
RU2007109518A (ru) 2008-09-27
NO20071369L (no) 2007-05-04
SI1778720T1 (sl) 2011-04-29
US20110269673A1 (en) 2011-11-03
ES2613027T3 (es) 2017-05-22
SG155211A1 (en) 2009-09-30
US8470769B2 (en) 2013-06-25
WO2006018652A2 (en) 2006-02-23
GB0703060D0 (en) 2007-03-28
DK1927597T3 (en) 2017-02-13
NZ584340A (en) 2010-09-30
EP1778720A2 (en) 2007-05-02
MX2007002057A (es) 2007-07-19
EP2096118A1 (en) 2009-09-02
KR20070083486A (ko) 2007-08-24
EP3147293A1 (en) 2017-03-29
BRPI0514420A (pt) 2008-06-10
CN101031583B (zh) 2013-06-05
CA2974538A1 (en) 2006-02-23
CN103360486A (zh) 2013-10-23
IL213319A (en) 2017-07-31
IL180727A (en) 2015-06-30
EP1927597B1 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
CY1113684T1 (el) Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη
CY1118243T1 (el) Νεα κατασκευασματα μεταφορεα και μορια συζευγματος φορτιου μεταφορεα
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
CY1113850T1 (el) Νεα παραγωγα ινσουλινης
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
CY1113898T1 (el) Συντηγμενο ετεροκυκλικο παραγωγο, φαρμακευτικη συνθεση η οποια το περιεχει και η χρηση του στην ιατρικη
BR0209434A (pt) Peptìdeos antimicrobianos e composições
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CY1109439T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
BR0311693A (pt) Sal de formato de o-desmetil-venlafaxina
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
FR2903903B1 (fr) Utilisation d'un hydrolysat de proteines de riz en tant que principe actif pigmentant
EA201070548A1 (ru) Производные кератина и способы их получения
CY1109882T1 (el) Νεα αλατα ατορβαστατινης και φαρμακευτικες συνθεσεις που τα περιεχουν
DK1198570T3 (da) Monomert protein af TGF-Beta-familien
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
DE60024100D1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
DE69900756D1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
CY1105550T1 (el) Μεμνο-πεπτιδια, μια διαδικασια για την παρασκευη και τη χρηση τους
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
BRPI0404006A (pt) Compostos de benzoindolina, processo para sua preparação e composições farmacêuticas contendo os mesmos
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen
CY1117399T1 (el) Συνθεσεις και μεθοδοι για προληψη και θεραπεια νευροεκφυλιστικων ασθενειων
WO2003095482A3 (fr) Nouveaux peptides cycliques, leur utilisation comme agents anti-microbiens.